These results, to our knowledge, are the first to indicate that silencing TGFBR1 and TAK1 attenuates osteogenic medium-induced vascular inflammation and calcification, and that the TGFBR1/TAK1 pathway plays a key role in the pathological process of vascular calcification. Here, MAP3K7 is linked to calcification.